NAS: DCPH
Before the Bell
--Quotes are delayed by 20 min
May 16, 2022, 7:09 a.m.
$
10.10
Change
-0.21 -2.04%
Volume
Volume 2
Quotes are delayed by 20 min
Previous close
$ 10.31
$ 10.31
Change
+0.35 +3.51%
Day low
Day high
$9.90
$10.38
52 week low
52 week high
$6.51
$38.91
Mr. Steven L. Hoerter President & Chief Executive Officer |
Mr. Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP |
Dr. Matthew L. Sherman Chief Medical Officer & Executive Vice President |
Dr. Rodrigo Ruiz Soto Senior Vice President-Clinical Development |
Dr. Daniel L. Flynn Chief Scientific Officer & Executive VP |
Dr. Stephen B. Ruddy Chief Technical Officer & SVP |
Mr. Daniel C. Martin Chief Commercial Officer & SVP |
Mr. Jeffrey M. Held General Counsel & Senior Vice President |
Mr. Jama Pitman Vice President-Regulatory & Quality Assurance |
Dr. James A. Bristol Chairman |
Dr. Susan L. Kelley Independent Director |
Mr. Ron Squarer Independent Director |
Mr. Franklin S. Friedman Independent Director |
Ms. Patricia L. Allen Independent Director |
Dr. Edward J. Benz Independent Director |
Mr. John R. Martin Independent Director |
Mr. Dennis L. Walsh Independent Director |
Coming up: Empire state survey factory activity in New York in May
Harpoon Therapeutics upgraded to outperform from neutral at Wedbush
Weber now sees full-year sales of $1.65 bln to $1.80 bln; FactSet consensus $2.1 bln
Target stock price target cut to $294 from $353 at Deutsche Bank
Quaker Houghton stock price target cut to $175 from $225 at Deutsche Bank
VF Corp. stock price target cut to $64 from $86 at Deutsche Bank
Carvana stock price target cut to $54 from $95 at Deutsche Bank
Dingdong double upgraded to overweight from underweight at J.P. Morgan
Dada Nexus upgraded to overweight from neutral at J.P. Morgan
IQIYI double upgraded to overweight from underweight at J.P. Morgan
Bilibili upgraded to neutral from underweight at J.P. Morgan
KE Holdings upgraded to neutral from underweight at J.P. Morgan
Virtual Stock Exchange